在 POLA 队列中，描述了 CNS WHO 3 级少突胶质细胞瘤 IDH 突变和 1p/19q 共缺失的三个病理组：组 1（仅高有丝分裂计数）、组 2（微血管增殖 MVP 且无坏死）和组 3 （MVP 和坏死）。POLA 队列中的 494 名患者被纳入其中，中位随访时间为 96 个月。为了确定第 1 组中病理组和对比增强对总生存期 (OS) 或无进展生存期 (PFS) 的影响，获得生存曲线（Kaplan-Meier 方法）并进行比较（对数秩检验）。还测试了临床因素和 CDKN2A 纯合缺失 HD 的预后价值。进行多变量分析。生存分析表明，病理组与无进展生存期（PFS P=0.01）和总生存期（OS P=0.001）相关。在第1组中，对比增强（1CE）的患者与没有对比增强的患者相比预后较差（OS P=0.028，PFS P=0.006）。进一步分层为第 1CE- 组、第 1CE 组、第 2 组和第 3 组提供了更清晰的预后区别（OS P=0.002，PFS P<0.0001）。其他预后因素包括年龄（OS P<0.0001，PFS P=0.002）、手术切除范围（OS P=0.001，PFS P=0.003）、KPS（OS P<0.0001，PFS P=0.002）、术后治疗（OS P=0.007，PFS P<0.0001），CDKN2A HD（OS 和 PFS P<0.0001）。在多变量分析中，病理分组对 PFS 仍具有预后意义。坏死和 CDKN2A HD 是 WHO 3 级少突胶质细胞瘤、IDH 突变和 1p/19q 共缺失的不良预后因素。此外，在第 1 组患者中，缺乏对比增强是预后较好的一个因素。© 作者 2024。由牛津大学出版社代表神经肿瘤学会出版。版权所有。如需商业重复使用，请联系 reprints@oup.com 获取转载和转载的翻译权。所有其他权限都可以通过我们网站文章页面上的权限链接通过我们的 RightsLink 服务获得 - 如需了解更多信息，请联系journals.permissions@oup.com。

In POLA cohort, three pathological groups of CNS WHO grade 3 oligodendroglioma IDH-mutant and 1p/19q co-deleted have been described: group 1 (high mitotic count only), group 2 (microvascular proliferation MVP and no necrosis), and group 3 (MVP and necrosis).494 patients from the POLA cohort, with a median follow up of 96 months were included. To identify the impact of the pathological groups and contrast enhancement in group 1 on overall survival (OS) or progression free survival (PFS), survival curves were obtained (Kaplan-Meier method) and compared (log-rank test). Prognostic value of clinical factors and CDKN2A homozygous deletion HD were also tested. Multivariate analysis was performed.Survival analysis demonstrated that the pathological groups were associated with both progression-free survival (PFS P=0.01) and overall survival (OS P=0.001). In group 1, patients with contrast enhancement (1CE+) had a poorer prognosis compared to those without (OS P=0.028, PFS P=0.006). Further stratification into group 1CE-, group 1CE+, group 2, and group 3 provided clearer prognostic distinctions (OS P=0.002, PFS P<0.0001). Other prognostic factors included age (OS P<0.0001, PFS P=0.002), extent of surgical resection (OS P=0.001, PFS P=0.003), KPS (OS P<0.0001, PFS P=0.002), postoperative treatment (OS P=0.007, PFS P<0.0001), and CDKN2A HD (OS and PFS P<0.0001). The pathological groups remained of prognostic significance for PFS in multivariate analysis.Necrosis and CDKN2A HD are adverse prognostic factors of WHO grade 3 oligodendrogliomas, IDH mutant and 1p/19q co-deleted. Besides, in group 1 patients, lack of contrast enhancement is a factor of better prognosis.© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.